BioLineRx (BLRX) Current Assets (2011 - 2026)

As of Dec 31, 2025, BioLineRx posted Current Assets of $23.68 million, down 12.6% from the prior year.

• Current Assets has declined for four consecutive years, though with a five-year compound annual growth rate of 0.7% (years ended Dec 2020 to Dec 2025).
• By year, Current Assets came in at $27.1 million in the year ended Dec 31, 2024 (-42.6%), $47.18 million in the year ended Dec 31, 2023 (-9.3%), $52 million in the year ended Dec 31, 2022 (-9.4%) and $57.4 million in the year ended Dec 31, 2021 (+150.9%).
• The figure for the quarter ended Jun 30, 2026 ranks as the lowest quarterly Current Assets in data going back to the quarter ended Sep 30, 2011.
• Year over year, Current Assets has now declined in each of the last seven quarters, with an average decline of 21.9% over the last eight quarters.
• The high point for year-over-year Current Assets in five years was the quarter ended Sep 30, 2021 (growth of 193.4%); the low point was the quarter ended Sep 30, 2023 (a decline of 50.3%).
• Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $21.58 million (quarter ended Mar 31, 2026), $23.68 million (quarter ended Dec 31, 2025) and $28.52 million (quarter ended Sep 30, 2025).